All News

Found 3,463 articles

• Seattle Genetics, Inc. And Bristol-Myers Squibb Company Announce Clinical Collaboration To Evaluate Combination Of Adcetris® (Brentuximab Vedotin) And Opdivo® (Nivolumab) In Hematologic Malignancies

  1/12/2015

• Meditope Biosciences Enhances Leadership Team With New Executive And Board Appointments

  1/7/2015

• Immunomedics, Inc. Appoints Dr. Francois Wilhelm Chief Medical Officer

  1/6/2015

• Conkwest, Sorrento Therapeutics, Inc. And NantWorks Announce Presentation At The 33rd Annual J. P. Morgan Healthcare Conference By Dr. Patrick Soon-Shiong

  1/6/2015

• Compugen Ltd. Discloses Initial Experimental Results For Predicted Antibody Drug Conjugate Targets

  1/5/2015

• Sorrento Therapeutics, Inc. To Present At The 2015 Biotech Showcase And 8th Annual OneMedForum In San Francisco

  1/5/2015

• Assurex Health Locks In $30 Million Financing Round

  12/24/2014

• ImmunoGen, Inc. Reports Roche Has Provided An Update On The MARIANNE Trial

  12/19/2014

• Sorrento Therapeutics, Inc. And Conkwest Announce Exclusive Global Collaboration

  12/19/2014

• Seattle Genetics, Inc. Initiates Phase 1b Trial Of SGN-CD33A In Combination With Frontline Standard Of Care And As Consolidation Therapy For Acute Myeloid Leukemia

  12/18/2014

• Biotech Billionaire Bets $20 Million On Sorrento Therapeutics, Inc.

  12/17/2014

• Crescendo Biologics' Receives Further Investment From Astellas Venture Management To Develop Novel Humabody Therapeutics Targeting Immune Checkpoint Inhibitors

  12/16/2014

• ImmunoGen, Inc. Announces Webcast Of Presentation At The 33rd Annual J.P. Morgan Healthcare Conference

  12/16/2014

• ImmunoGen, Inc. Announces Webcast Of Presentation At The 33rd Annual J.P. Morgan Healthcare Conference

  12/15/2014

• Immunomedics, Inc. Reports Expanded Phase 1/2 Trials Confirm Activity And Good Safety Profile Of Sacituzumab Govitecan (Immu-132) In Patients With Advanced Triple-Negative Breast Cancer

  12/12/2014

• Abzena PLC Release: Interim Results For The Six Months Ended 30 September 2014

  12/11/2014

• MultiCell Technologies Inc. Files Novel Antibody-Drug Conjugate Patent Application

  12/10/2014

• Seattle Genetics, Inc. Presents Data From Novel Antibody-Drug Conjugate SGN-CD33A At American Society of Hematology Annual Meeting

  12/9/2014

• Seattle Genetics, Inc. And Takeda Report Phase 3 AETHERA Clinical Trial Data From ADCETRIS® (Brentuximab Vedotin) In Post-Transplant Hodgkin Lymphoma Patients At Risk Of Relapse At American Society of Hematology Annual Meeting

  12/8/2014

• Seattle Genetics, Inc. And Takeda Announce Four-Year Survival Data From ADCETRIS® (Brentuximab Vedotin) Pivotal Trial In Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma At American Society of Hematology Annual Meeting

  12/8/2014